You are here

  • Home
  • Archive
  • Volume 11, Issue 10
  • Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D

Article metrics

Article menu
Clinical/translational cancer immunotherapy
Original research
Phase II study of durvalumab and tremelimumab with front-line neoadjuvant chemotherapy in patients with advanced-stage ovarian cancer: primary analysis in the original cohort of KGOG3046/TRU-D

 

Online download statistics by month:

Online download statistics by month: October 2023 to July 2025

AbstractFullPdf
Oct 2023398400137
Nov 2023307307123
Dec 202314414590
Jan 202412312489
Feb 202410310357
Mar 202410510699
Apr 202410410660
May 2024828350
Jun 2024969655
Jul 202411111358
Aug 20247676182
Sep 2024858558
Oct 2024858654
Nov 202412612766
Dec 202412112337
Jan 2025777750
Feb 202519619637
Mar 2025747459
Apr 202511011069
May 2025484837
Jun 2025343423
Jul 2025110
Total260626201490